News | November 16, 2024
IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Total Income in Q2 FY25 stood at Rs. 532.18 crore
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Construction of the plant will commence in 2025 with first production expected to be in 2027
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Subscribe To Our Newsletter & Stay Updated
